Abstract
The objective is to determine the number of appointments required to titrate patients diagnosed with heart failure with reduced ejection fraction (HFrEF), to the maximum tolerated dose (MTD) of angiotensin-converting enzyme inhibitor (ACEi), angiotensin-receptor blocker (ARB) and angiotensin receptor neprilysin inhibitor (ARNI) (sacubitril/valsartan) medications. Secondly, we aim to estimate the cost of outpatient appointments to titrate medicines.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
